SEOUL (Reuters) – South Korea’s Celltrion Inc said on Monday its experimental treatment of COVID-19 demonstrated a 100-fold reduction in viral load of the disease in animal testing.
The pharmaceutical company said the first in-human clinical trials of the treatment are set to start in July.
(Reporting by Joyce Lee; Editing by Himani Sarkar)
